Patient characteristics, treatment patterns, and health outcomes among COPD phenotypes

被引:19
作者
Allen-Ramey, Felicia C. [1 ]
Gupta, Shaloo [2 ]
DiBonaventura, Marco daCosta [3 ]
机构
[1] Merck & Co Inc, Global Hlth Outcomes, West Point, PA USA
[2] Kantar Hlth, Hlth Outcomes Practice, Princeton, NJ USA
[3] Kantar Hlth, Hlth Outcomes Practice, New York, NY 10010 USA
关键词
chronic obstructive pulmonary disease; emphysema; chronic bronchitis; quality of life; work productivity; health care resource use; OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-LIFE; UNITED-STATES; ACTIVITY IMPAIRMENT; WORK PRODUCTIVITY; TIOTROPIUM; IMPACT; EXACERBATIONS; PREVENTION; SALMETEROL;
D O I
10.2147/COPD.S35501
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Recent literature has suggested that emphysema and chronic bronchitis, traditionally considered to be entities overlapping within chronic obstructive pulmonary disease (COPD), may be distinct disorders. Few studies have examined the differences in patient characteristics and health outcomes between these conditions. This study examined whether COPD phenotypes represent distinct patient populations, in a large nationally representative US sample. Methods: Data were obtained from the 2010 US National Health and Wellness Survey (NHWS). NHWS respondents (n = 75,000) were categorized as a COPD phenotype based on their self-reported diagnosis of COPD only (n = 970), emphysema only (n = 399), or chronic bronchitis only (n = 2071). Phenotypes were compared on demographics, health characteristics, treatment patterns, health outcomes, work productivity, and resource use. Variables were compared using Chi-square and analysis of variance tests for categorical and continuous outcomes, respectively. Health outcomes were also examined using regression modeling, controlling for demographic and health characteristic covariates. Results: Patients with chronic bronchitis were significantly younger (51.38 years versus 63.24 years for COPD versus 63.30 years for emphysema, P < 0.05) and more likely to be employed (46.98% versus 23.81% for COPD versus 28.33% for emphysema, P < 0.05). Relative to the other phenotypes, patients with chronic bronchitis were also significantly more likely to be female, nonwhite, and to exercise currently (all P < 0.05), and were significantly less likely to be a current or former smoker (P < 0.05). Controlling for demographic and health characteristics, patients self-identified as having COPD only reported significantly worse physical quality of life (adjusted mean 36.69) and health utilities (adjusted mean 0.65) and significantly more absenteeism (adjusted mean 7.08%), presenteeism (adjusted mean 30.73%), overall work impairment (adjusted mean 34.06%), and activity impairment (adjusted mean 46.59%) than the other phenotypes (all P < 0.05). Conclusion: These results suggest considerable heterogeneity among different COPD phenotypes with respect to demographics, health characteristics, disease characteristics, treatment patterns, and health outcomes. Research aimed at understanding the differences in patient characteristics and disease presentation of these phenotypes could be used to guide treatment recommendations.
引用
收藏
页码:779 / 787
页数:9
相关论文
共 30 条
[21]   Treatment and quality of life in patients with chronic obstructive pulmonary disease [J].
Miravitlles, M ;
Alvarez-Sala, JL ;
Lamarca, R ;
Ferrer, M ;
Masa, F ;
Verea, H ;
Zalacain, R ;
Murio, C ;
Ros, F ;
Vidal, R .
QUALITY OF LIFE RESEARCH, 2002, 11 (04) :329-338
[22]   Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? [J].
Molken, Maureen P. M. H. Rutten-Van ;
Ostenbrink, Jan B. ;
Tashkin, Donald P. ;
Burkhart, Deborah ;
Monz, Brigitta U. .
CHEST, 2006, 130 (04) :1117-1128
[23]   THE VALIDITY AND REPRODUCIBILITY OF A WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT INSTRUMENT [J].
REILLY, MC ;
ZBROZEK, AS ;
DUKES, EM .
PHARMACOECONOMICS, 1993, 4 (05) :353-365
[24]   Chronic obstructive pulmonary disease in non-smokers [J].
Salvi, Sundeep S. ;
Barnes, Peter J. .
LANCET, 2009, 374 (9691) :733-743
[25]   The impact of chronic obstructive pulmonary disease on work loss in the United States [J].
Sin, DD ;
Stafinski, T ;
Ng, YC ;
Bell, NR ;
Jacobs, P .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 165 (05) :704-707
[26]   The proportional Venn diagram of obstructive lung disease - Two approximations from the United States and the United Kingdom [J].
Soriano, JB ;
Davis, KJ ;
Coleman, B ;
Visick, G ;
Mannino, D ;
Pride, NB .
CHEST, 2003, 124 (02) :474-481
[27]   Health-related quality of life is related to COPD disease severity [J].
Ståhl E. ;
Lindberg A. ;
Jansson S.-A. ;
Rönmark E. ;
Svensson K. ;
Andersson F. ;
Löfdahl C.-G. ;
Lundbäck B. .
Health and Quality of Life Outcomes, 3 (1)
[28]   Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD [J].
Vogelmeier, Claus ;
Hederer, Bettina ;
Glaab, Thomas ;
Schmidt, Hendrik ;
Rutten-van Molken, Maureen P. M. H. ;
Beeh, Kai M. ;
Rabe, Klaus F. ;
Fabbri, Leonardo M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (12) :1093-1103
[29]  
Ware JE, 2002, The SF-12v2TM how to score version 2 of the SF-12® health survey:(with a supplement documenting version 1)
[30]   The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide [J].
Wedzicha, Jadwiga A. ;
Calverley, Peter M. A. ;
Seemungal, Terence A. ;
Hagan, Gerry ;
Ansari, Zainab ;
Stockley, Robert A. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 177 (01) :19-26